Ser345
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Phosphorylation Site Page:
Ser345 - PR (human)

Site Information
AFAPPRSsPCASSTP   SwissProt Entrez-Gene
Predicted information:  Scansite
Orthologous residues: PR (rat): (S344), PR iso2 (human): (S181), PR (mouse): (S343), PR (chicken): (S259)
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450157

In vivo Characterization
Methods used to characterize site in vivo: [32P] bio-synthetic labeling (6, 8), electrophoretic mobility shift (8), immunoprecipitation (1), mass spectrometry (5), mutation of modification site (3, 4), peptide sequencing (8), phospho-antibody (1, 2, 4), phosphopeptide mapping (6, 8), western blotting (1, 2)
Disease tissue studied: breast cancer (1, 2, 4, 6, 8)
Relevant cell line - cell type - tissue: COS (fibroblast) (1, 3), HeLa (cervical) (1, 2), SF9 (5, 6), T47D (breast cell) (1, 2, 4, 6, 8)

Controlled by
Treatments: AG1478 (4), asoprisnil (2), EGF (4), lonaprisan (2), onapristone (2), PP2 (4), progestin_R5020 (1, 2, 4, 5, 8), RU-486 (2), SB203580 (4), U0126 (4)

Downstream Regulation
Effects of modification on PR: molecular association, regulation (4)
Effects of modification on biological processes: transcription, induced (4, 7)
Induce interaction with: SP1 (human) (4)


References

1

Hagan CR, Knutson TP, Lange CA (2013) A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res 41, 8926-42
23921636   Curated Info

2

Busia L, Faus H, Hoffmann J, Haendler B (2011) The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression. Mol Cell Endocrinol 333, 37-46
21138753   Curated Info

3

Wardell SE, Narayanan R, Weigel NL, Edwards DP (2010) Partial Agonist Activity of the Progesterone Receptor Antagonist RU486 Mediated by an Amino-Terminal Domain Coactivator and Phosphorylation of Serine400. Mol Endocrinol 24, 335-45
20008003   Curated Info

4

Faivre EJ, Daniel AR, Hillard CJ, Lange CA (2008) Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol 22, 823-37
18202149   Curated Info

5

Knotts TA, et al. (2001) Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem 276, 8475-83
11110801   Curated Info

6

Beck CA, et al. (1996) Stoichiometry and site-specific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system. J Biol Chem 271, 19546-55
8702648   Curated Info

7

Takimoto GS, et al. (1996) Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors. J Biol Chem 271, 13308-16
8662865   Curated Info

8

Zhang Y, et al. (1995) Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol 9, 1029-40
7476977   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.